ARTES Biotechnology has announced a collaboration with global pharmaceutical company, Boehringer Ingelheim Animal Health. ARTES Biotechnology specialises in recombinant protein production, process and vaccine development from microbial expression systems. ARTES’ expression system Hansenula polymorpha is the preferred technology for affordable mass vaccination and recommended by the World Health Organization (WHO) for these purposes. In combination with ARTES’ METAVAX® platform, this offers a new, unique and economical approach to low-cost mass production of safe and effective vaccines required in the veterinary field.
US – Governor Terry E. Branstad travelled to Sioux Center last week to attend the grand opening for one of three Boehringer Ingelheim Vetmedica, Inc. (BIVI) specialised vaccine research facilities.
BARCELONA, SPAIN - An important anniversary in the history of porcine circovirus type 2 (PCV2) has been marked at a special international pig veterinary satellite symposium held in Barcelona, Spain in June 2011 as part of the 6th International Symposium on Emerging and Re-emerging Pig Diseases.
4th Boehringer Ingelheim Expert Forum on Farm-Animal Well-Being
Boehringer Ingelheim is proud to announce the 2nd Boehringer Ingelheim IPVS Ileitis symposium during the IPVS 2006 congress in Copenhagen. The Symposium will take place on July 17 from 16.45h - 18.00h at the Congress Centre; Auditorium 15.
Read and download the posters.
Boehringer Ingelheim Vetmedica, Inc., (BIVI) announces Drs. Keith Bretey, Erin Johnson, Jeff Okones and Brian Payne, all professional service veterinarians for the company’s swine division, completed the Executive Veterinary Program (EVP) for Swine Health and Production program at the University of Illinois.
Get the latest news on Swine Health Subscribe to our newsletter